Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
Jan‐Niklas Eckardt(Else Kröner-Fresenius-Stiftung), Jan Moritz Middeke(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Martin Bornhäuser(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Carsten Müller‐Tidow(University of Cologne), Claudia D. Baldus(German Cancer Research Center), Markus Wolfien(Zimmer Biomet (Germany)), Christoph Schliemann(University Hospital Münster), Martin Sedlmayr(Zimmer Biomet (Germany)), Andreas Burchert(University Hospital Schleswig-Holstein), Sebastian Stasik(University Hospital Carl Gustav Carus), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hubert Serve(University Hospital Münster), Waldemar Hahn(Zimmer Biomet (Germany)), Martin Kaufmann(Robert Bosch Hospital), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Johannes Schetelig(German National Bone Marrow Donor Registry), Christian Thiede(University Hospital Carl Gustav Carus), Christoph Röllig(University Hospital Carl Gustav Carus)
Cited by 58
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
The future landscape of large language models in medicine
|Communications Medicine|2023|937